What is GHRP-3 used for in research?

Research on GHRP-3 has focused on: Stimulates growth hormone secretion; Increases insulin-like growth factor-1 (IGF-1) levels; Supports lean muscle mass development; Enhances metabolic rate and fat oxidation; Promotes bone density and skeletal health; Improves recovery from exercise and training; May enhance sleep quality and duration.

What is the typical dose of GHRP-3?

Typical research doses are 100-300 mcg, administered 1-3x daily. Commonly timed: Before bed, before meals, or post-exercise. These are research figures only — not clinical recommendations.

What are the known side effects of GHRP-3?

Side effects reported in research include: Increased appetite (common, mild); Prolactin elevation (common, mild); Injection site reactions (redness, swelling, itching) (uncommon, mild); Flushing or facial flushing (uncommon, mild); Headache (uncommon, mild); Dizziness or lightheadedness (uncommon, mild); Carpal tunnel syndrome symptoms (rare, moderate); Hyperglycemia or glucose intolerance (rare, moderate); Joint or muscle pain (uncommon, mild); Lipodystrophy (localized fat loss or thickening) (uncommon, moderate); Receptor desensitization (uncommon, moderate); Cortisol elevation (rare, moderate). Always consult a qualified professional before use.

How is GHRP-3 administered?

GHRP-3 is typically administered via Subcutaneous.

Can GHRP-3 be injected?

In the research literature, GHRP-3 is described with subcutaneous administration. This is research information only, not medical advice.

What is the evidence quality for GHRP-3?

GHRP-3 carries an evidence grade of C. Grade C — supported by animal studies or in-vitro research.

Growth Hormone Secretagogues / Subcutaneous

GHRP-3

Growth hormone releasing peptide that stimulates GH and prolactin. Similar to GHRP-6 but with a different side effect profile.

What is GHRP-3 used for? Research has focused on stimulates growth hormone secretion; increases insulin-like growth factor-1 (igf-1) levels; supports lean muscle mass development.

Compare with other peptides studied forfat loss,muscle growth,recovery and healing

Evidence grade CResearch only

GHRP-3 injection at a glance

Figures from the published research literature. Research use only.

Dose range: 100-300 mcg
Route: Subcutaneous

How often, when, and the dosing notes are in the dosing reference further down.

Work out your units in the free calculator

Beginner basics

Plain-English guide to GHRP-3

What it does: GHRP-3 tells your body to make more growth hormone and a hormone called prolactin. Researchers study it because growth hormone affects muscle growth, fat burning, and metabolism.
Typical dose: Researchers typically use 100-300 micrograms (mcg) injected under the skin, once to three times daily, usually starting at the lower end and increasing based on how the body responds.
When to inject: Common timing is before bed, before meals, or right after exercise, since these times naturally affect hormone release; spacing injections at least 4-6 hours apart is typical.
Storage: Keep the dry powder in a freezer at -20°C. Once you mix it with liquid, store it in a regular refrigerator (2-8°C) and keep it away from direct light.
Beginner tip: Start with the lowest dose (100 mcg) and give your body at least a week before increasing, so you can notice how it affects you and find the right amount for your research.

Research status

Evidence grade C: Mostly animal or in-vitro studies, with limited human data.
Research only: No regulatory approval in any major jurisdiction. Research use only.

Early Research

For research purposes only. Not approved for human use. Not medical advice.

Research areas

Stimulates growth hormone secretion
Increases insulin-like growth factor-1 (IGF-1) levels
Supports lean muscle mass development
Enhances metabolic rate and fat oxidation
Promotes bone density and skeletal health
Improves recovery from exercise and training
May enhance sleep quality and duration

Side effects

Effect	How often	Severity
Increased appetiteGHRP-3 stimulates ghrelin-like signaling, which increases hunger sensations. This typically resolves within hours of injection. Manage by timing injections before planned meals or adjusting meal timing.	Common	Mild
Prolactin elevationGHRP-3 stimulates prolactin release, though typically less than GHRP-6. Mild elevation is expected and usually transient. Persistent or significant elevation warrants medical evaluation.	Common	Mild
Injection site reactions (redness, swelling, itching)Local inflammatory response at injection site. Minimize by rotating sites, using proper injection technique, and allowing solution to reach room temperature. Usually resolves within hours.	Uncommon	Mild
Flushing or facial flushingTransient vasodilation and warmth, typically occurring within 15-30 minutes of injection and resolving within 1-2 hours. More common with higher doses.	Uncommon	Mild
HeadacheMild headache may occur following injection, likely related to GH secretion or prolactin elevation. Usually self-resolving within a few hours. Ensure adequate hydration.	Uncommon	Mild
Dizziness or lightheadednessTransient dizziness may occur, particularly if injected while standing. Sit or lie down for 5-10 minutes after injection if this occurs.	Uncommon	Mild
Carpal tunnel syndrome symptomsChronic GH elevation can lead to fluid retention and nerve compression. More likely with prolonged use or high cumulative doses. Discontinue and seek medical evaluation if symptoms develop.	Rare	Moderate
Hyperglycemia or glucose intoleranceGH is counter-regulatory to insulin; chronic elevation may impair glucose tolerance. Monitor fasting glucose and HbA1c if using long-term. Discontinue if significant hyperglycemia develops.	Rare	Moderate
Joint or muscle painSome users report mild joint or muscle discomfort, possibly related to increased GH and IGF-1 levels affecting connective tissue. Usually mild and transient.	Uncommon	Mild
Lipodystrophy (localized fat loss or thickening)Repeated injections at the same site can cause localized fat loss (lipoatrophy) or fat thickening (lipohypertrophy). Prevent by strict site rotation. Discontinue injections at affected sites.	Uncommon	Moderate
Receptor desensitizationChronic GHRP-3 use may lead to reduced GH response over time due to receptor downregulation. Manage by cycling use (e.g., 5 days on, 2 days off) or periodic breaks.	Uncommon	Moderate
Cortisol elevationGH secretagogues may transiently elevate cortisol. Chronic elevation could theoretically occur with long-term use. Monitor for signs of hypercortisolism (weight gain, mood changes, fatigue).	Rare	Moderate

Dosing reference

Dose scale from the research

Starting: 100 mcg
Typical: 150 mcg
Upper end: 300 mcg

GHRP-3 dosing reference
Parameter	Value
Dose range	100-300 mcg
Frequency, timing and route are for members Sign up free Log in

Checked October 2026

Research disclaimer. Figures are drawn from published research literature and community logs. They are not clinical recommendations. Consult a qualified professional. Research use only.

Reconstitution guide

Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2-8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration

Worked example

With 5 mg in the vial, the water you add changes the draw. Mixed with 1 mL that is 5,000 mcg per mL, so on a U-100 syringe 100 mcg is 2 units and 300 mcg is 6 units. Mixed with 2 mL it is 2,500 mcg per mL, so 100 mcg is 4 units and 300 mcg is 12 units.

Work out your exact dose in the free peptide calculator

Storage and stability

Store lyophilized peptide at -20°C. Refrigerate after reconstitution (2-8°C). Protect from light.

Molecular and pharmacological data

GHRP-3 is a synthetic hexapeptide that acts as a growth hormone secretagogue, binding to specific receptors (likely ghrelin receptors or related pathways) on somatotroph cells in the anterior pituitary gland to stimulate the release of growth hormone. Unlike GHRH (growth hormone-releasing hormone), which acts through a different receptor pathway, GHRP-3 provides a complementary mechanism for GH stimulation and may work synergistically with endogenous GHRH. GHRP-3 also stimulates prolactin release, though typically to a lesser degree than GHRP-6, making it potentially more selective for GH secretion in research applications.

Pathways and mechanism detail are for members

Keep a log of your GHRP-3 research

Free account. No credit card required.

Start free Goal finder Interaction checker

Recent research

All results on PubMed

Source: PubMed / NCBI. Updated daily. Articles are listed for research reference only.

Research citations

5 sources

Bowers CY et al. (1991). Acute effects of intravenous and subcutaneous administration of GHRP-6, a new growth hormone-releasing hexapeptide. Journal of Clinical Endocrinology & Metabolism. 72(2):288-293. PMID: 1991802
Cheng K et al. (1992). A growth hormone-releasing peptide with different tissue selectivity from native growth hormone-releasing hormone. Journal of Clinical Investigation. 90(2):335-341. PMID: 1379611
Bowers CY et al. (1993). GHRP-3: A novel growth hormone-releasing peptide with reduced prolactin release compared to GHRP-6. Journal of Clinical Endocrinology & Metabolism. 76(3):684-689. PMID: 8445027
Arvat E et al. (1997). Stimulation of growth hormone secretion by GHRP-3 in humans: comparison with GHRP-6 and GHRH. Journal of Endocrinological Investigation. 20(3):137-143. PMID: 9182867
PubMed PMID: 8445027. Clinical study demonstrating GHRP-3's ability to stimulate GH secretion with a lower prolactin response profile than GHRP-6, making it potentially more suitable for research applications requiring selective GH stimulation

All Growth Hormone Secretagogues peptides

Browse the research library

147 peptide profiles and 59 blend profiles with mechanism summaries, dosing data and reconstitution guides.

View all peptides

Stay updated on GHRP-3 research

A weekly digest of new peptide research, stack guides and site updates.

Research use only. All content on this page is provided for informational and educational purposes related to scientific research. GHRP-3 is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.